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Background: Patients with recent stroke or TIA are at high risk for new vascular events. Several evidence based
strategies in secondary prevention of stroke are available but frequently underused. Support programs with
multifactorial risk factor modifications after stroke or TIA have not been investigated in large-scale prospective
controlled trials so far. INSPiRE-TMS is a prospective, multi-center, randomized open intervention trial for intensified
secondary prevention after minor stroke and TIA.
Methods/design: Patients with acute TIA or minor stroke admitted to the participating stroke centers are screened
and recruited during in-hospital stay. Patients are randomised in a 1:1 ratio to intervention (support program) and
control (usual care) arms. Inclusion of 2.082 patients is planned. The support program includes cardiovascular risk
factor measurement and feedback, monitoring of medication adherence, coaching in lifestyle modifications, and
active involvement of relatives. Standardized motivational interviewing is used to assess and enhance patients’
motivation. Primary objective is a reduction of new major vascular events defined as nonfatal stroke and myocardial
infarction or vascular death. Recruitment time is planned for 3.5 years, follow up time is at least 2 years for every
patient resulting in a total study time of 5 years (first patient in to last patient out).
Discussion: Given the high risk for vascular re-events in acute stroke and the available effective strategies in
secondary prevention, the INSPIRE-TMS support program has the potential to lead to a relevant reduction of
recurrent events and a prolongation of the event-free survival time. The trial will provide the basis for the decision
whether an intensified secondary prevention program after stroke should be implemented into regular care. A
cost-effectiveness evaluation will be performed.
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Patients with recent stroke or TIA are at high risk for a
recurrent stroke or other major vascular events [1-4].
Despite this high risk and the availability of evidence
based secondary prevention strategies, risk factor control
and medication adherence frequently remain under
recommended targets [5].
This observation has a variety of reasons: Although at
much higher risk, post-stroke patients do often not re-
ceive more intensive medical care than patients in pri-
mary prevention [4,6]. The separation of health systems
in hospital-based and outpatient care as in Germany is a
major barrier for optimal secondary prevention as recom-
mendations given in the acute stroke facility are frequently
not followed by primary care physicians (in part depend-
ing on their specialty) [4]. Another problem is that despite
a high motivation for optimal secondary prevention
shortly after experiencing the initial cerebrovascular event,
many patients don’t stick with the recommended mea-
sures over a longer time period. One-third of stroke
patients discontinue secondary prevention medication [7]
and control of arterial hypertension as the most important
risk factor for stroke remains unsatisfactory across coun-
tries [4,8].
Positive experiences with structured support programs
have been gained in other diseases such as diabetes mellitus
[9], coronary heart syndrome [10,11] and arterial hyperten-
sion [12] yielding better quality of risk factor control and
remarkable reductions in clinical event rates [10,13].
Considering the typical stroke and TIA population which
consists mainly of elderly patients frequently having mul-
tiple risk factors and a high risk for dependency after a re-
current event, a structured supported secondary prevention
program after stroke appears promising. However, it has
never been tested in an adequately powered trial. As a con-
sequence, stroke has not been selected for chronic disease
management programs.
A recent observation strengthens the hypothesis that
patients with cerebrovascular disease are likely to benefit
from a multimodal secondary prevention scheme. Inten-
sified medical treatment in patients with symptomatic
arterial stenosis (forming the control arm and compared
against stenting) was associated with a more than 50%
lower recurrence rate in the SAMMPRIS trial [14] com-
pared to patients with the same inclusion criteria but
non supported secondary prevention in the WASID trial
[15]. However this effect was not observed in a face-to-face
trial but in a comparison with a historical cohort.
The INSPiRE-TMS trial is therefore designed to eva-
luate the effects of a structured support program focus-
sing on cardiovascular risk factor control, monitoring of
medication adherence, coaching in lifestyle modifica-
tions, and active involvement of relatives over a period
of at least 2 years.Methods/design
Study design
INSPIRE is a prospective, multi-center, randomized open
intervention trial for intensified secondary prevention
initiated and coordinated by the Center for Stroke Re-
search Berlin. Approval was obtained by the local ethics
committee (EA2/084/11). The study has been registered at
the trial registration (clinicaltrials.gov: 01586702).Objectives
Primary objective: With regard to new vascular events
the study shall prove that the participation in a patient-
centered intensified secondary prevention program
increases the event-free survival time during follow
up compared to the participation in usual care.
Secondary objectives:
 To improve risk factor control and adherence to
medical recommendations
 To evaluate the effect of optimized secondary
prevention on surrogate parameters such as physical
fitness, vascular changes on retinal fundus and silent
vascular lesions in MRI
 To evaluate the influence of body weight and other
metabolic parameters on vascular event rates in
secondary prevention
 To calculate the cost-effectiveness of the support
program.Participants
Acute patients withTIA (clinical restitution within 24 hours
and ABCD2-Score ≥3 or visible DWI-lesion in MRI) or
minor stroke (mRS ≤ 2 at time of screening and visible
DWI-lesion in MRI) evaluated in a dedicated and organized
setting of care (Stroke Unit, out-patient clinic) in Germany
and Denmark will be included in the study. Participating
study centres are the Departments of Neurology at the
Charité-University Medicine Berlin, Campus Benjamin
Franklin, Campus Virchow-Klinikum and Campus Mitte,
the Department of Neurology, Klinikum rechts der Isar at
the Technische Universität of Munich, the Department of
Neurology at the Klinikum Ludwigshafen (all in Germany),
and the Department of Neurology at the University of
Aarhus, Denmark.
Inclusion criteria: Age over 18 years; acute stroke or
TIA within 14 days prior to inclusion into the study; at
least one of the following risk factors: arterial hyperten-
sion, diabetes mellitus, atrial fibrillation and/or smoking;
written informed consent, and realistic perspective in
keeping the outpatient appointments.
Exclusion criteria: Distance from home to study center
not in suitable range for keeping the outpatient appoint-
ments, cognitive impairment jeopardizing adherence to
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of study inclusion, malignant disease with life expectancy
of less than 3 years, relevant alcohol or other substance
abuse (except for nicotine), stroke or TIA aetiology with-
out options for evidence based secondary prevention (e.g.
dissection or vasculitis).
Recruitment and randomization
Consecutive acute patients with TIA or minor stroke admit-
ted to the Stroke Units or TIA clinics of the participating
centers will be included during in-hospital or in-clinic stay.
Patient recruitment is planned over a 3.5-years period.
Follow-up is planned for a minimum of 2 years for every pa-
tient after study inclusion in order to complete the 2 years
intervention program in all patients. Therefore the study
time from first patient in to last patient out is 5 years in total.
After approval from the participants and completion of
the initial assessment, patients will be formally entered
into the study and randomized with a 1:1 randomization
to intervention and control arm by a web-based online
randomization procedure provided by the Coordination
Center for Clinical Studies (KKS) at the Charité.
Procedures
Study procedures are depicted in the flow chart (Figure 1).
Standardized baseline assessment for intervention and
control groups will include a questionnaire regarding
demographic information, risk factors and co-morbidities,
clinical symptoms of the acute cerebrovascular event, and
duration of symptoms.
Standard clinical evaluation will consist of a neuro-
logical examination according to the National Institutes
of Health Stroke Scale (NIHSS) at admission and modi-
fied Rankin Scale (mRS) as well as Barthel Index (BI) atFigure 1 Flow chart of study procedures.time of study inclusion. Stroke aetiology will be classified
according to TOAST criteria [16]. Laboratory measures
will include LDL cholesterol, CRP, HbA1c, and INR.
Body mass index (BMI, kg/m2) will be calculated from
height and weight measurements. Blood pressure will be
measured manually in sitting patients (resting at least
5 min) on both arms. Both blood pressure values will be
recorded and the higher value will be used for statistical
comparisons. Arterial hypertension is defined by either
repeated elevated systolic blood pressure >140 and/or
diastolic blood pressure >90 mm Hg or the previous use
of antihypertensive drugs. Diabetes is defined by either
HbA1c ≥6.5% or use of antidiabetics. Hyperlipidemia is
defined by either LDL cholesterol > 100 mg/dl or use of
lipid-lowering drugs. Smoking will be evaluated in num-
ber of cigarettes per day and in pack years. Patients who
currently don’t smoke will be divided in non-smokers
and past smokers (within the last 5 years). The time
since smoking cessation will be documented. Physical
activity is measured as frequency of “physical activity
with an intensity leading to transpiration and/or elevated
breathing frequency over more than 30 min” per week.
Detailed and structured information concerning vascular
risk factor targets will be given to the patients before
discharge and these recommendations will be included
in the discharge letter to primary care physicians (PCP)
irrespective of the trial allocation.
Standard care will consist of outpatient care usually
guided by a primary care physician. The treating pri-
mary care physician will be informed about the
results of risk factor measurements at the yearly
follow-up appointments but no further recommenda-
tions will be given to the patient or PCP by the study
team.
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The target values for secondary prevention are orien-
tated at the recommendations of the German Society
of Neurology respective the European Stroke Organ-
isation. For patients with high recurrence risk in large
vessel disease (see above), targets are adapted on the
basis of “aggressive medical treatment” of the SAMM-
PRIS trial [14].
The intensified support program is planned with a
total of eight outpatient appointments. The structured
assessment will include risk factor control, medication
intake, compliance with oral anticoagulation therapy
(including monitoring of INR in Vitamin K antagonist
treatment) and joint agreement on an individual target
plan.
Target values for risk factors are:
 Blood pressure <140/85 mmHg (<130/80 in diabetic
patients) [16]
 Physiological circadian blood pressure with >10%
lower BP values during nighttime
 HbA1c <7.5%
 Nicotine abstinence
 LDL <100 mg/dl in patients with arterial or
cardioembolic stroke without specifically elevated
risk, LDL ≤70 mg/dl with CHD, LDL ≤70 mg/dl in
patients with symptomatic intracranial stenosis
judged as hemodynamically relevant (independent
from examination technique) or extracranial stenosis
>50% according NASCET criteria without surgical
intervention, LDL ≤70 mg/dl in patients with
evidence of instable plaque (in plaque imaging) in
the corresponding extracranial artery
 Physical activity ≥30 min per day at least three times
per week (oriented at the recommendations of the
German Society of Neurology
 Healthy nutrition (intake of 4–5 portions of fruit
and/or vegetables per day)
The targets for pharmaceutical treatment are:
 Platelet inhibitors for all patients with Stroke/TIA
caused by small or large vessel disease
 Dual antiplatelet therapy over three months in
patients with symptomatic intracranial stenosis
judged as hemodynamically relevant (independent
from examination technique) or extracranial stenosis
>50% (according NASCET) without surgical
intervention or in patients with evidence of instable
plaque (in plaque imaging) in corresponding
extracranial artery
 Oral anticoagulation (INR 2–3) or regular intake of
new oral anticoagulants in patients with atrial
fibrillation Statin treatment (Simvastatin 40 mg or Atorvastatin
80 mg) in patients with LDL >100 mg/dl or LDL
≤70 mg/dl in patients with high recurrence risk.
Intervention strategies:
 Comprehensive and repeated information about
pathophysiology of the individual risk for recurrent
event of stroke or TIA and potentials of vascular risk
reduction. This information will be offered to the
patients during in-hospital stay but also as part of the
outpatient appointments. Next of kin will be involved
as much as possible.
 An individual plan regarding target values and
medication will be agreed upon with the patient using
methods of motivational interviewing
 The patient’s motivation will be enhanced using feed-
back-strategies regarding measured risk factors, target
measurements (e.g. INR) and “memory parameters”
such as HbA1c or physical fitness
 Complementary offers: assistance in finding peer
groups and group therapies (e.g. nordic walking, INR
self measurement and smoking cessation programs).
Required certificates and training for involved profes-
sionals and treatment algorithms:
 Patients will receive counseling by board certified
physicians with special training in neurovascular
medicine at all intervention appointments.
Preparation for medical counseling by assessment
of risk factor control can be performed by trained
nurses or healthcare assistants.
 A standardized motivational interviewing training
over 2 days and reinforcement training over one
day after approximately 6 months is compulsory
for all physicians involved in counseling during
appointments in the support program.
 Standard operating procedures are used for
concrete action in case of critical deviations from
target values regarding blood pressure and
anticoagulation.
 Information about risk factor control is
communicated to family doctors via standardized
reports including telephone conversation in case of
urgently needed action or aimed interdisciplinary
consensus.Study endpoints
Primary endpoint
Composite of non fatal stroke (including strokes with
new tissue-based definition), non fatal major coronary
event and cardiovascular death.
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 Rate of patients who meet the recommended
guideline targets regarding blood pressure,
smoking cessation, serum-LDL, physical activity,
HbA1c (in patients with diabetes), therapeutic
range of INR or regular intake of new oral
anticoagulants in patients with atrial fibrillation,
 Effects on vascular surrogate parameters
(microalbuminuria, physical fitness,)
 Total mortality
 Frequency of hospital admissions for vascular
diseases (including TIA, angina pectoris with
vascular interventions, peripheral arterial occlusive
disease with vascular intervention)
 Number of days “alive and at home”.Substudy endpoints
Effects on vascular surrogate parameters (intima-media-
thickness status of retinal fundus “cerebrovascular lesion
load” in MRI), effects on quality of life and mood, cost
effectiveness, correlation between risk factor control,
surrogate parameters and biomarkers (exploratory).Power and sample size calculation
The expected event rate in the control arm was estimated
on the basis of the results of more recently published stud-
ies [2,3,6,17]. The expected relative risk reduction was cal-
culated in a conservative way only on the basis of blood
pressure reductions and irrespective of additional effects
of other risk factor modifications.
The effect size (relative risk reduction) was estimated
on the basis of the observed effects of blood pressure
reduction in recent secondary prevention trials [1,18]
and the mean blood pressure differences between two
consecutive cohorts evaluated in the Charité hospitals in
Berlin [19]. The first cohort was observational and
represented standard care in Berlin. The second cohort
underwent a stepwise modeled support program that
included up to four outpatient appointments over a
period of 6 months, using the same strategies as
described above. The basis of the sample size estimation
is an expected event rate of 16.94% after three years in
the control group and a relative risk reduction of 28% in
the intervention group resulting from relative risk reduc-
tions per mmHg in other secondary prevention studies.
The sample size was calculated assuming an aimed
power of 80%. After consideration of a non-adherence
rate of 10% in the intervention group and a drop-out
rate of 5% in both arms, the case number results in
2.082 patients (1.041 patients per group).
After analysis of mean blood pressure differences in
the 1-year follow-up of the first 500 patients, theexpected effect size and the power calculation will be re-
adjusted.
Statistical analysis
The primary analysis is a time to event analysis using
Cox-regression-models. An interim analysis after 160
observed events will be done by a statistician blinded to
the study arm. The interim analysis will indicate whether
the sample size and study duration has to be modified
according to the overall observed event rate. The sample
size needs not to be adjusted for this blinded interim ana-
lysis as only the overall event rate will be considered. The
assessment of the true drop out rate will be part of the
(blinded) interim analysis. The dichotomized secondary
endpoints will be evaluated according to the primary
outcome measure. Continuous variables will be analyzed
with the appropriate tests. The clustering of the data
by the different centres will be accounted for by using
frailty models [20].
Methods against BIAS
Follow-up assessment are planned to be done by study
nurses not involved in providing the individual support
program for the patient aiming to keep them blinded to
the study allocation. Endpoints will be assessed in a writ-
ten questionnaire that will be handed out to the patients
prior to further follow-up assessments.
The primary endpoints and serious adverse events will
be verified and adjudicated by the Endpoint and SAE
Adjudication Committee that is blinded to the trial allo-
cation of the individual patients.
Ethical considerations
The trial does not include any experimental treatments
but compares usual care with more intensive care based
on national and international guidelines aiming at an
improved adherence to evidence based recommenda-
tions. The study has been approved by the Ethics Com-
mittee of the Charité (EA2/084/11). Patients are insured
against travel accidents.
Discussion
Depending on aetiology, the natural risk for stroke re-
currence during the first year after event has been
described between 5% [2] (stroke patients without high
risk factors) and 20% [15,21-24]. A secondary ischemic
event has considerably more serious consequences lead-
ing to physical disability in more than 60% and death in
more than 20% [25]. In addition to the medical and per-
sonal impact of the recurrent stroke, the costs of recur-
rent events and rehospitalisation are enormous. Lifetime
costs per first ever stroke case are more than 40.000
Euro in Germany [26].
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up with consequent initiation of multimodal preventive
measures results in a major reduction of re-events. In
patients with TIA, the “effect of urgent treatment of
transient ischemic attack and minor stroke on early re-
current stroke” (EXPRESS) study was conducted as a
population based sequential comparison [27]. It demon-
strated that urgent assessment of stroke aetiology and
early start of secondary prevention was associated with
reduced risk for recurrent stroke. The interventions
comprised immediate start of poly-pharmaceutical risk
factor control, antithrombotic therapy and interventional
treatment for symptomatic carotid stenosis. However,
patients were followed-up for only three months. Very
similar effects were found in the SOS-TIA study with
much lower recurrence rates as expected according to
the ABCD [2] score [17].
Hence, it seems of crucial importance to start a sec-
ondary prevention program at an early stage after the
cerebrovascular event. This is particularly important be-
cause shortly after the index event, patients are generally
very motivated for participation in a structured support
program.
In contrast to other diseases such as diabetes mellitus,
coronary heart disease and COPD, stroke has not been
selected for chronic disease management programs in
Germany. Therefore, neither hospitals nor primary care
physicians are able to offer intensive monitoring of
cardiovascular risk factors to patients after stroke or
TIA. Recommendations given in discharge letters fre-
quently focus on medical treatments but not on recom-
mendations regarding non-pharmacological treatments
such as life style modifications including physical activ-
ities and dietary aspects. Family members are usually not
involved in the treatment concepts. Since lifestyle is
strongly influenced by the social network, patients fre-
quently continue the unhealthy lifestyle. Smoking, poor
diet coupled with physical inactivity and alcohol con-
sumption are still leading causes of mortality [28].
While the primary objective of INSPiRE-TMS is to investi-
gate the effects of a structured multifactorial support pro-
gram on the vascular re-event-free survival time, a number
of completed or ongoing randomized studies examine effects
of supported secondary prevention on differences in risk fac-
tor control, medication adherence or surrogate parameters.
To our knowledge, none of them has been adequately pow-
ered to detect a difference in vascular recurrence free sur-
vival time [29-38].
Some limitations of the study will need to be consid-
ered: First, there is a potential contamination effect in
patients who are randomized to the control group. With
the information given before randomization and during
follow-up visits, these patients may be better informed
about effective vascular prevention compared to thenormal post-stroke population. This effect is frequently
seen in prospective controlled trials. However, it seems
unlikely that this contamination will lead to the same
effect as the structured intervention program. Second,
the information about life style parameters, adverse
events and endpoint events will be self-reported. Thus,
self-reported errors are to be expected in both groups
and expectation bias by study personnel may occur in
follow-up documentation. In order to control for these
biases, follow-up assessment is planned to be done by
study nurses blinded to the trial arm and not involved
in the individual support program. The primary end-
points and serious adverse events will be documented
in a written form by the patient prior to the follow-
up-interview and will be adjudicated by a blinded End-
point Committee. Third, the study is conducted in two
European health systems and generalizability of the
study results may therefore be questioned. However, the
methods of intervention are standardized as far as pos-
sible in individual counseling and both the quality of
risk factor control and rate of recurrent events will be
described in detail in the control and intervention arms.
This should allow a projection of the study results into
other health systems.
In summary, the INSPiRE-TMS trial is designed to an-
swer the question whether a structured support program
for secondary prevention after a cerebrovascular event is
effective in reducing new major vascular events. The
results of the trial are expected for the year 2016.
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